2. Search Result
Search Result
Results for "

Fc fragments

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

4

Biochemical Assay Reagents

1

Peptides

33

Inhibitory Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108829
    Abatacept
    1 Publications Verification

    CTLA4lg; BMS-188667

    		 CTLA-4 Inflammation/Immunology Cancer
    Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
    Abatacept
  • HY-147305
    Efgartigimod alfa

    ARGX-113

    		 Fc Receptor (FcR) Inflammation/Immunology
    Efgartigimod alfa (ARGX-113) is a reversibility, humanized Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research .
    Efgartigimod alfa
  • HY-P990688
    Xaluritamig

    AMG-509

    		 CD3 Cancer
    Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 + T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma .
    Xaluritamig
  • HY-P99115
    Envafolimab

    ASC 22; KN 035

    		 PD-1/PD-L1 Cancer
    Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors .
    Envafolimab
  • HY-108829A
    Abatacept (powder)
    1 Publications Verification

    CTLA4lg (powder); BMS-188667 (powder); Orencia

    		 CTLA-4 Inflammation/Immunology Cancer
    Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
    Abatacept (powder)
  • HY-P99777
    Ontorpacept
    1 Publications Verification

    TTI-621

    		 CD47 Cancer
    Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
    Ontorpacept
  • HY-P99665
    Insulin efsitora alfa

    LY-3209590

    		 Insulin Receptor Metabolic Disease
    Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .
    Insulin efsitora alfa
  • HY-P99437
    Anbenitamab
    1 Publications Verification

    KN-026

    		 EGFR Cancer
    Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer .
    Anbenitamab
  • HY-P99667
    Ipafricept
    4 Publications Verification

    OMP-54F28; FZD8-Fc

    		 Wnt Cancer
    Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
    Ipafricept
  • HY-P99879
    Efbemalenograstim alfa

    Benegrastim; Bineuta; F 627

    		 STAT Inflammation/Immunology
    Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells .
    Efbemalenograstim alfa
  • HY-P990256
    Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9)

    		CTLA-4 Inflammation/Immunology Cancer
    Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) is a mouse-derived IgG2a κ type antibody inhibitor targeting to mouse CTLA-4/CD152. Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) can be used for the researches of cancer and immunology, such as colon .
    Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9)
  • HY-P990172
    Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2)

    		PD-1/PD-L1 Cancer
    Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) can be used for the research of cancer.
    Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2)
  • HY-P990171
    Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)

    		PD-1/PD-L1 Cancer
    Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG2a. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) can be used for the research of cancer.
    Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)
  • HY-P991513
    BI-655064

    		TNF Receptor Inflammation/Immunology
    BI-655064, a humanised anti-CD40 antibody with has fragment crystallisable (Fc) regions with two mutations that prevent Fc-mediated antibody-dependent or complement-mediated cellular cytotoxicity and platelet activation. BI-655064 can be used for the study of autoimmune disease, such as lupus nephritis and rheumatoid arthritis (RA) .
    BI-655064
  • HY-E70364
    IgdE protease

    		Biochemical Assay Reagents Inflammation/Immunology
    IgdE protease is a cysteine protease, which is initially isolated from Streptococcus agalactiae. IgdE protease digests monoclonal antibodies (mAbs) of the IgG1 type specifically at their upper hinge region, produces Fc/2, hinge peptide dimers, and Fab fragment. IgdE protease can be used in disulfide bonds and free thiol analysis, as it requires no reducing agents for cleavage .
    IgdE protease
  • HY-P990269
    Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1)

    		TNF Receptor Inflammation/Immunology Cancer
    Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD40L/CD154. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a chimeric version of the original MR-1 antibody (HY-P990134). The variable domain sequences are identical to the original MR-1 but the constant region sequences have been switched from Armenian hamster IgG to mouse IgG2a. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) blocks CD40/CD40L signaling. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) can be used for researches of cancer, inflammation and immunology.
    Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1)
  • HY-NP193A
    Rat IgG Fc fragment

    		Fc Receptor (FcR) Inflammation/Immunology
    Rat IgG Fc fragment is a crystallizable fragment (Fc) of rat immunoglobulin G (IgG) molecules that can be used as an immunolabel in various immunoassays, including ELISA.
    Rat IgG Fc fragment
  • HY-P99844
    Davoceticept

    ALPN-202; CD80 vIgD-Fc

    		 CTLA-4 Cancer
    Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
    Davoceticept
  • HY-P991676
    Eflumenibep alfa

    DS-2325A

    		 Kallikrein Inflammation/Immunology
    Eflumenibep alfa is a Kallikrein 5 inhibitor with anti-inflammatory activity. Eflumenibep alfa is a fusion protein that combines human SPINK2 with the human IgG1 Fc fragment at the C-terminus .
    Eflumenibep alfa
  • HY-P991678
    Efpixileukin alfa

    XENP-27564; XMAB-27564

    		 Interleukin Related Inflammation/Immunology
    Efpixileukin alfa is a fusion protein that combines human IL-2 variant fused at the C-terminus to human immunoglobulin G1 (IgG1) Fc fragment. Efpixileukin alfa is an immunomodulator .
    Efpixileukin alfa
  • HY-NP0197A
    Goat IgG Fc fragment

    		Fc Receptor (FcR) Inflammation/Immunology
    Goat IgG Fc fragment is a crystallizable fragment (Fc) of goat immunoglobulin G (IgG) molecules that can be used as an immunolabel in various immunoassays, including ELISA.
    Goat IgG Fc fragment
  • HY-P991680
    Elipunercept

    		TNF Receptor Inflammation/Immunology
    Elipunercept is a fusion protein that combines human TNFRSF1B extracellular domain fragment (1-235) fused at the C-terminus to a human IgG1 Fc fragment. Elipunercept is an immunomodulator .
    Elipunercept
  • HY-P991158
    Rinvatercept

    		TGF-β Receptor Neurological Disease
    Rinvatercept, a fusion protein, is a glycyl (1)-chimeric N-terminal (1-108)-peptide (2-109) combined from the sequences of the extracellular domains of the human ACVR2A/B, and is fused via a G3 peptide linker (110-112) to an immunoglobulin G1 (IgG1) Fc fragment. Rinvatercept can be used for research of neuromuscular disease .
    Rinvatercept
  • HY-P99913
    Eflapegrastim

    		c-Fms Inflammation/Immunology Cancer
    Eflapegrastim is a composite protein consisting of a genetically modified granulocyte-colony stimulating factor (GCSF) molecule linked via a chemical bond to an IgG4 Fc fragment (LAPS-carrier). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .
    Eflapegrastim
  • HY-E70365A
    IdeS (Immobilized, Microspin)

    		Biochemical Assay Reagents Inflammation/Immunology
    IdeS (Immobilized, Microspin) is a resin that covalently couples IdeS protease to agarose beads and cleaves IgG at specific sites to generate F(ab')2 and Fc fragments. After IdeS (Immobilized, Microspin) digestion, F(ab')2 and Fc fragments are obtained in the solution without IdeS enzyme.
    IdeS (Immobilized, Microspin)
  • HY-E70566
    Protease (Fab Cleaving)

    		Ser/Thr Protease Others
    Protease (Fab Cleaving) is a serine protease expressed recombinantly in E.coli with a 6×His tag at the C-terminus. Protease (Fab Cleaving) specifically digests human IgG1 at a single site above the hinge, generating intact Fab and Fc fragments within two hours without reducing conditions.
    Protease (Fab Cleaving)
  • HY-NP0196D
    Mouse IgG Fc fragment

    		Fc Receptor (FcR) Inflammation/Immunology
    Mouse IgG Fc fragment is a crystallizable fragment (Fc) of mouse immunoglobulin G (IgG) molecules that can be used as an immunolabel in various immunoassays, including ELISA.
    Mouse IgG Fc fragment
  • HY-NP0198A
    Rabbit IgG Fc fragment

    		Fc Receptor (FcR) Inflammation/Immunology
    Rabbit IgG Fc fragment is a crystallizable fragment (Fc) of rabbit immunoglobulin G (IgG) molecules that can be used as an immunolabel in various immunoassays, including ELISA.
    Rabbit IgG Fc fragment
  • HY-P990986
    Efdelikofusp alfa

    		Interleukin Related Inflammation/Immunology Cancer
    Efdelikofusp alfa is a bispecific Fc fusion protein. Efdelikofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of human immunoglobulin G4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efdelikofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.
    Efdelikofusp alfa
  • HY-P990992
    Efzilonkofusp alfa

    GI-102

    		 Interleukin Related Inflammation/Immunology Cancer
    Efzilonkofusp alfa is a bispecific Fc fusion protein. Efzilonkofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of human immunoglobulin G4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efzilonkofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.
    Efzilonkofusp alfa
  • HY-P991235
    FS102

    BMS-986186

    		 EGFR Caspase Cancer
    FS102 is a selective Fc fragment with antigen binding (Fcab) that targets HER2 with a KD value of 0.8 nM. FS102 induces the degradation of HER2, activates Caspase 3/7 and disrupts the integrity of the cell membrane, triggering apoptosis of tumor cells. FS102 is promising for research of cancers such as breast cancer, gastric cancer, and colorectal cancer .
    FS102
  • HY-P990304B
    Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1)

    		TNF Receptor Infection Inflammation/Immunology Cancer
    Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) is a mouse-derived IgG1 κ antibody inhibitor that targets mouse 4-1BBL/CD137L. Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) is a chimeric version of the original TKS-1 antibody (HY-P990304). The variable domain sequences are identical to the original TKS-1 but the constant region sequences have been switched from rat IgG2a to mouse IgG1. Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) reacts with mouse 4-1BB ligand (4-1BBL). Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) can be used for the researches of cancer, infection, inflammation and immunology.
    Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1)
  • HY-P990270
    Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1)

    		TNF Receptor Inflammation/Immunology Cancer
    Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse CD40L/CD154. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) is a chimeric version of the original MR-1 antibody (HY-P990134). The variable domain sequences are identical to the original MR-1 but the constant region sequences have been switched from Armenian hamster IgG to mouse IgG1. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) blocks CD40/CD40L signaling. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) can be used for researches of cancer, inflammation and immunology.
    Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1)
  • HY-P990304C
    Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1)

    		TNF Receptor Infection Others Inflammation/Immunology Cancer
    Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) is a mouse-derived IgG2a κ antibody inhibitor that targets mouse 4-1BBL/CD137L.Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) is a chimeric version of the original TKS-1 antibody (HY-P990304). The variable domain sequences are identical to the original TKS-1 but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) reacts with mouse 4-1BB ligand (4-1BBL). Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) can be used for the researches of cancer, infection, inflammation and immunology.
    Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1)
  • HY-P991921
    TNX-1500

    		TNF Receptor Fc Receptor (FcR) Cardiovascular Disease Endocrinology
    TNX-1500 is a crystallizable fragment-modified anti-CD154 antibody. TNX-1500 contains the hu5c8 fragment antigen-binding (Fab) domain from Ruplizumab (HY-P99315) and an IgG4 Fc region engineered to reduce FcγRIIa binding. TNX-1500 has significantly weaker binding affinity to FcγRI, FcγRIIaH, FcγRIIbF, FcγRIIIaF, and FcγRIIIaV compared to hu5c8 (Kd values: 8.7 nM, 7100 nM, 4900 nM, 8000 nM, 6000 nM respectively). TNX-1500 prolongs nonhuman primate renal allograft survival, prolongs nonhuman primate cardiac allograft survival. TNX-1500 can be used for the research of allograft rejection [1] [2].
    TNX-1500
  • HY-P992109
    Eftezirleukin alfa

    		Interleukin Related Inflammation/Immunology
    Eftezirleukin alfa is a human immunoglobulin G4 (IgG4) Fc fragment. Eftezirleukin alfa is associated with IL-2 .
    Eftezirleukin alfa
  • HY-P11746
    GPLGIAGQC

    		MMP Cancer
    GPLGIAGQC is an MMP2-cleavable peptide . In nanoparticle-drug conjugation systems, GPLGIAGQC is cleaved by MMP2 between the glycine and isoleucine residues. After MMP2-mediated hydrolysis of GPLGIAGQC, the Fc fragment is exposed on the surface of nanoparticles .
    GPLGIAGQC
  • HY-P992232
    Anti-GFRA4 Antibody (scFv)

    		RET Inflammation/Immunology
    Anti-GFRA4 Antibody (scFv) is a recombinant single-chain antibody fragment targeting GFRA4. Anti-GFRA4 Antibody (scFv) is formed by connecting the variable region of the heavy chain (VH) and the variable region of the light chain (VL) through a flexible short peptide (Linker), without the Fc segment, while maintaining the antigen-binding specificity.
    Anti-GFRA4 Antibody (scFv)
  • HY-P992154
    Ricefidase

    KJ-103

    		 Human leukocyte immunoglobulin (Ig)-like receptors (LILR) Infection Inflammation/Immunology
    Ricefidase (KJ-103) is a recombinant human immunoglobulin G-degrading enzyme. Ricefidase efficiently cleaves human IgG at the hinge region. Ricefidase rapidly reduces IgG levels. Ricefidase has low immunogenicity and clears AAV neutralizing antibodies. Ricefidase is applicable to research related to desensitization of all IgG subclasses and improvement of the suitability of AAV-based gene therapy .
    Ricefidase

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: